• SENSEX 73,257.62
    -341.05 (--0.46%)
  • BANKNIFTY 53,974.90
    -391.80 (--0.72%)
  • NSE
    1,766.00 1,640.25(%)
  • Reliance Industries
    1,160.50 1,152.30(%)
  • Piramal Pharma
    235.45 231.85(%)
  • Larsen & Toubro
    3,892.00 4,440.00(%)
  • Billionbrains
    189.95 227.00(%)
  • United Breweries
    1,316.00 1,845.90(%)
  • HDFC Bank
    687.15 1,017.90(%)
  • Cholaman.Inv.&Fn
    1,555.00 1,952.00(%)
  • Lenskart Solut.
    697.50 725.00(%)
  • HDFC AMC
    2,317.50 2,901.00(%)
  • Jubilant Ingrev.
    581.55 535.30(%)
  • Acutaas Chemical
    3,690.00 1,571.20(%)
  • One 97
    1,640.50 1,856.50(%)
  • Ola Electric
    37.44 51.84(%)
  • Sahajanand Medi
    478.00 347.50(%)
  • Swiggy
    183.05 174.30(%)
  • Bajaj Finance
    918.00 1,177.60(%)
  • Infosys
    1,103.50 980.30(%)
  • Patanjali Foods
    352.00 613.95(%)
  • Netweb Technol.
    4,490.00 5,810.00(%)
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison
Overview
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison

Rubicon Research Ltd Pharmaceuticals - Indian - Formulations

  • Indian Private
  • BSE Code : 34163.0
  • ISIN : INE506V01022
1,509.60 19 (1.30%)
  • As on 28 Oct 2026 (EOD)

  • Today’s Low

    1,486.30

  • Today’s High

    1,533.70

  • Open

    1,500.00

  • Perv Close

    1,490.30

  • 52W Low

    576.00

  • 52W High

    1,899.00

Key Indicators

  • P/E(TTM)

    106.54

  • Mar.Cap (₹Cr.)

    24,988.70

  • Div & Yield %

    0.10

  • Book Value(₹)

    81.76

  • Debt-Equity Ratio

    1.30

  • AGM Date

    27-Oct-2026

  • EPS

    14.22

  • P/E Ratio

    106.54

Financials Ratios

  • Debt-Equity Ratio

    1.11

  • Mar.Cap (₹Cr.)

    24,988.70

  • RONW (%)

    27.11

  • ROCE (%)

    18.42

Score Board

  • Equity (₹ in Cr.)

    16.55

  • BV (₹)

    81.80

  • Sales( ₹ in Cr.)

    1,306.08

  • NP (in Cr.)

    188.89

  • NP Var(%)

    12.0

  • Div%

    150.0

  • CPS (₹)

    13.70

  • EPS (₹)

    11.40

  • Traded Value (₹ in Lakhs)

    25,077.26

  • 52 Week High

    1,899.00

  • 52 Week Low

    576.00

  • Price BSE

    1515.0

  • Price NSE

    1,510.00

  • Market Capital( in Cr.)

    25,077.26

  • P/C Ratio

    110.70

  • P/E Ratio

    132.80

  • Price Vs.BV

    11.40

View More
Invest Now!

Navigate The Market With Confidence

Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions

Financials

All Values are in (₹Cr)
Particulars(INCOME) 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar
INCOME :            
Sales Turnover 1,306.08 1,073.84 630.51 393.52 400.04 331.35
Excise Duty 0.00 0.00 0.00 0.00 0.00 0.00
Net Sales 1,306.08 1,073.84 630.51 393.52 400.04 331.35
Other Income 10.83 19.68 26.43 25.48 17.38 10.74
Stock Adjustments 33.36 10.94 10.70 49.24 -8.75 5.83
Total Income 1,350.27 1,104.46 667.64 468.24 408.67 347.92
EXPENDITURE :            
Raw Materials 381.08 319.22 225.15 149.40 94.55 61.15
Power and Fuel Cost 24.25 20.01 18.31 15.71 10.19 6.54
Employee Cost 164.27 127.74 84.71 97.12 59.29 41.29
Other Manufacturing Expenses 132.88 89.09 60.55 50.11 40.30 21.46
Selling and Administration Expenses 307.11 250.73 171.79 104.28 83.51 63.76
Miscellaneous Expenses 19.20 8.10 7.58 7.66 63.39 31.58
Employee Benefit Expenses 164.27 127.74 84.71 97.12 59.29 41.29
Less: Preoperative Expenditure 0.00 0.00 0.00 0.00 0.00 0.00
Total Expenses 1,028.78 814.89 568.09 424.28 351.21 225.77
Operating Profit 321.49 289.58 99.56 43.97 57.45 122.15
Interest 30.96 34.29 30.53 18.96 9.02 9.00
Gross Profit 290.53 255.29 69.03 25.01 48.43 113.15
Depreciation 37.75 32.01 34.95 36.06 31.51 27.77
Profit Before Tax 252.78 223.28 34.08 -11.05 16.92 85.38
Current Tax 68.43 57.92 11.24 8.32 2.78 21.18
Fringe Benefit tax 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax -3.81 -2.18 -1.51 -2.48 -2.54 11.25
Reported Net Profit 188.17 167.54 24.35 -16.89 16.68 52.96
Extraordinary Items -0.73 -0.85 0.01 0.03 0.36 0.00
Adjusted Net Profit 188.90 168.39 24.34 -16.92 16.32 52.96
Adjustment below Net Profit 6.23 1.96 0.00 0.00 0.01 -0.04
P & L Balance brought forward 368.28 199.09 174.99 42.49 146.18 94.26
Statutory Appropriations 0.00 0.00 0.00 0.00 0.00 0.00
Appropriations 0.31 0.30 0.25 0.25 0.51 1.00
P & L Balance carried down 562.36 368.28 199.09 25.34 162.36 146.18
Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Preference Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Equity Dividend (%) 150.00 2.00 2.00 5.00 0.00 0.00
Dividend Per Share(Rs) 1.50 0.02 0.02 0.50 0.00 0.00
Earnings Per Share-Unit Curr 11.40 10.87 1.60 -33.31 32.91 104.46
Earnings Per Share(Adj)-Unit Curr 11.40 - - - - -
Book Value 81.97 43.33 31.29 564.84 845.39 811.56
Book Value(Adj)-Unit Curr 81.97 - - - - -

Shareholding Pattern

  • Promoter Group

    51.25%

  • Public Share Holding

    48.75%

Category of Shareholder No of Shares % Holdings Demat Shares Shareholders
A]. Promoter & Group
Foreign (Promoter & Group) - Bodies Corporate 45,258,360 27.34 45,258,360 1
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign) 0 0.00 0 0
Foreign Promoter(Institutional) 0 0.00 0 0
Promoter Others 0 0.00 0 0
Sub Total 45,258,360 27.34 45,258,360 1
[2] INDIAN
Bodies Corporate-Indian (Promoter & Group) 0 0.00 0 0
Government(Central / State)-Indian (Promoter & Group) 0 0.00 0 0
Directors & their Relatives-Indian (Promoter & Group) 0 0.00 0 0
Financial Institutions / Banks-Indian (Promoter & Group) 0 0.00 0 0
Individuals / Hindu Undivided Family-Indian (Promoter & Group) 39,060,000 23.60 39,060,000 5
Partnership Firms-Indian (Promoter & Group) 510,000 0.31 510,000 1
Persons Acting in Concert 0 0.00 0 0
Trusts 0 0.00 0 0
Others 0 0.00 0 0
Sub Total 39,570,000 23.90 39,570,000 6
Total ShareHolding for Promoter & Group
B]. Publice Share Holding
1] Institution
Government(Central / State) 0 0.00 0 0
Clearing Members 0 0.00 0 0
Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
Financial Institutions / Banks 0 0.00 0 0
Foreign Bank 0 0.00 0 0
Foreign Bodies Corporate/OCBs/FBC 0 0.00 0 0
Foreign Collaborators 0 0.00 0 0
Foreign Institutional Investors 14,908,298 9.01 14,908,298 70
Foreign Venture Capital Investors 0 0.00 0 0
Foreign Institution Other 0 0.00 0 0
Insurance Companies 258,630 0.16 258,630 2
Mutual Funds / UTI 22,809,842 13.78 22,809,842 20
Individuals (Non-Resident / Foreign) 0 0.00 0 0
NSDL Intransit 0 0.00 0 0
Others 2,959,359 1.79 2,959,359 19
Trusts 0 0.00 0 0
Venture Capital Funds 0 0.00 0 0
Sub total 40,936,129 24.73 40,936,129 111
2] Non Institution
Bodies Corporate 636,883 0.38 636,883 241
Clearing Members 80,885 0.05 80,885 20
Directors of their Relatives 0 0.00 0 0
Employees 0 0.00 0 0
Escrow Account 0 0.00 0 0
Foreign Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
NRIs/Foreign Individuals/Foreign Nationals 2,957,618 1.79 2,957,618 693
Foreign Non Institution Other 6,605,156 3.99 6,605,156 2
Hindu Undivided Families 22,548,770 13.62 22,548,770 853
Indian Public 0 0.00 0 0
Individuals holding nominal share capital in excess of Rs. 1 lakh 920,717 0.56 920,717 3
Individuals holding nominal share capital up to Rs. 1 lakh 5,526,623 3.34 5,526,623 36,059
Market Maker 0 0.00 0 0
NSDL Transit 0 0.00 0 0
Shares in transit 0 0.00 0 0
Societies 0 0.00 0 0
Trust & Foundation 0 0.00 0 0
Others 455,901 0.28 455,901 1
Sub Total 39,767,419 24.02 39,767,419 37,900
Total Public Shareholding
C]. Shares held by Custodians and against which Depository Receipts have been issued
ADR 0 0.00 0 0
GDR 0 0.00 0 0
Other Custodians 0 0.00 0 0
Total Shares held by Custodians and against which Depository Receipts have been issued 0 0.00 0 0
Grand Total ( A + B + C ) 165,531,908 100.00 165,531,908 38,018

Company Background

Rubicon Research LtdPharmaceuticals - Indian - Formulations

  • Rubicon Research Ltd
  • BSE Code : 34163.0
  • ISIN : INE506V01022

  • Incorporation Year

    1999

  • Registered Office

    Medone House B-75 Road No.33
    Wagle Estate, Thane (West),
    Maharashtra-400604

  • Telephone

    022 6141 4000

  • FAX

  • Chairman

    Venkat Changavalli

  • Managing Director

    Pratibha Pilgaonkar

  • Company Secretary

    Deepashree Tanksale

  • Auditor

    Deloitte Haskins & Sells LLP

  • Face Value

    1

  • Listing

    NSE

  • Registrar

    MUFG Intime India Pvt Ltd
    C-101 247 Park,
    L B S Marg,Vikhroli West
    Mumbai - Mumbai-400083

Rubicon Research Ltd Peer Comparison

Profit & Loss
Financial Ratios
Balance Sheet
Select Company Name LTP (₹) Revenue Sales P/E Ratio ROCE %
Rubicon Research 1,514.95 1,316.91 1,306.08 106.54 20.82
Abbott India 25,488.50 7,217.19 6,929.05 33.54 43.78
Astrazeneca Phar 6,073.10 2,304.07 2,275.58 89.51 27.86
Glaxosmi. Pharma 2,488.75 3,932.76 3,790.20 39.76 58.17
Novartis India 1,847.40 393.10 354.33 46.65 15.94
Cipla 1,350.00 20,102.60 18,979.95 41.15 13.88
Bliss GVS Pharma 643.55 773.53 729.81 59.81 12.51
Amrutanjan Healt 490.45 520.13 502.55 26.27 24.16
Fermenta Biotec. 449.00 474.15 450.25 20.96 18.77
Guj. Themis Bio. 352.45 168.25 165.82 94.24 18.05
Ambalal Sarabhai 35.40 19.52 3.94 65.56 6.77